Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014 (2014), Article ID 186212, 10 pages
Clinical Study

Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival

1Skin Cancer Unit, CHU Hôtel-Dieu, 1 Place Alexis Ricordeau, 44093 Nantes, France
2CRCNA, INSERM U892, CNRS 6299, 9 Quai Moncousu, 44093 Nantes, France
3PIMESP-SEB, Hôpital St Jacques, 85 rue St Jacques, 44093 Nantes, France
4Service d’Anatomie et Cytologie Pathologiques, CHU Hôtel-Dieu, 30 boulevard Jean Monnet, 44093 Nantes, France
5Plateforme de Génétique des Cancers, CHU Hôtel-Dieu, 1 Place Alexis Ricordeau, 44000 Nantes, France
6Unité de Thérapie Cellulaire et Génique (UTCG), CHU Hôtel-Dieu, 9 Quai Moncousu, 44093 Nantes, France

Received 19 July 2013; Revised 18 November 2013; Accepted 6 December 2013; Published 8 January 2014

Academic Editor: Ana Parente Pereira

Copyright © 2014 Amir Khammari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Two first analyses of our clinical trial on TIL as adjuvant therapy for melanoma were published in 2002 and 2007. We present here an update of the clinical results after a 17-year median followup. In this trial, disease-free patients were randomly assigned to receive either TIL/IL-2 or IL-2. The relapse-free survival (RFS) was the primary objective. Eighty-eight patients were enrolled. A new analysis performed in May 2013 did not show significant changes in RFS or OS duration. However, our first finding on the association between the number of invaded lymph nodes and TIL effectiveness was strengthened. The Cox model adjusted on this interaction showed for the first time a significant treatment effect when considering the overall population, both on the RFS and OS. Patients treated with TIL had a longer RFS () or OS (). This study being with a very long followup (17 years), confirmed the association between TIL effectiveness and the number of invaded lymph nodes, indicating that a low tumor burden could be a crucial factor enhancing the curative effect of TIL in possible microscopic residual disease. Moreover, we confirmed that a prolonged survival was associated with the presence of specific TIL and a decrease in Foxp3 expression.